DNTH
Dianthus Therapeutics, Inc.
$109.13
+1.03
(+0.95%)
Mkt Cap
6.10B
Volume
630,724
52W Range
30.2-117.88
Sector
Healthcare
Beta
0.08
EPS (TTM)
-0.13 USD
P/E Ratio
-9.81
Revenue (TTM)
1.90M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (162.34M) | (84.97M) | (43.55M) | (28.48M) | (13.11M) | (74.94M) | (76.77M) | (57.52M) | (35.49M) | (9.43M) |
| EPS | -4.20 | -2.55 | -8.45 | -7.60 | -3.82 | -27.30 | -33.18 | -27.62 | -16.05 | -4.27 |
| Free Cash Flow | (129.27M) | (78.28M) | (36.97M) | (29.21M) | (60.80M) | (64.42M) | (60.16M) | (49.56M) | (24.46M) | (6.67M) |
| FCF / Share | -3.42 | -2.35 | -7.17 | -7.79 | -17.70 | -23.47 | -26.01 | -23.80 | -11.07 | -3.02 |
| Operating CF | (129.06M) | (78.18M) | (36.86M) | (29.07M) | (59.53M) | (64.02M) | (57.10M) | (41.89M) | (22.26M) | (6.53M) |
| Total Assets | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M | 161.62M | 161.51M | 157.31M | 54.46M | 11.34M |
| Total Debt | 1.39M | 1.49M | 585,000 | 788,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 51.09M | 22.79M | 132.32M | 15.37M | 131.65M | 58.15M | 65.07M | 58.34M | 51.57M | 4.54M |
| Book Value | 493.40M | 352.48M | 168.87M | 73.66M | 172.67M | 143.91M | 141.19M | 145.65M | 50.32M | 9.04M |
| Return on Equity | -0.33 | -0.24 | -0.26 | -0.39 | -0.08 | -0.52 | -0.54 | -0.39 | -0.71 | -1.04 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 761,000 | 463,000 | 284,000 | 396,000 | 193,000 | 1.16M | 1.33M | 2.17M | 1.86M | 874,000 | 457,000 | 924,000 |
| Net Income | (50.22M) | (40.83M) | 97.91M | (36.77M) | (31.63M) | (29.51M) | (28.44M) | (25.17M) | (17.61M) | (13.75M) | (10.56M) | (14.76M) |
| EPS | -0.90 | -0.85 | 2.59 | -0.97 | -0.88 | -0.82 | -0.81 | -0.74 | -0.51 | -0.54 | -2.33 | -3.78 |
| Free Cash Flow | (49.16M) | (28.87M) | (47.12M) | (30.56M) | (23.94M) | (27.65M) | (27.48M) | (21.29M) | (14.54M) | (14.97M) | (11.86M) | 1.64M |
| FCF / Share | -0.88 | -0.60 | -1.25 | -0.81 | -0.67 | -0.77 | -0.78 | -0.62 | -0.42 | -0.58 | -2.62 | 0.42 |
| Operating CF | (48.98M) | (28.86M) | (46.98M) | (30.55M) | (23.89M) | (27.63M) | (27.44M) | (21.27M) | (14.53M) | (14.94M) | (11.85M) | 1.50M |
| Total Assets | 1.21B | 1.25B | 530.92M | 577.45M | 326.08M | 348.58M | 374.01M | 354.25M | 368.96M | 382.46M | 179.41M | 192.46M |
| Total Debt | 1.29M | 1.36M | 1.39M | 1.28M | 1.33M | 1.40M | 1.49M | 311,000 | 407,000 | 497,000 | 585,000 | 670,000 |
| Cash & Equiv | 110.55M | 627.67M | 51.09M | 55.98M | 13.24M | 10.12M | 22.79M | 33.67M | 314.17M | 329.72M | 132.32M | 157.28M |
| Book Value | 1.17B | 1.20B | 493.40M | 546.45M | 303.08M | 328.61M | 352.48M | 337.90M | 358.22M | 372.69M | 168.87M | 178.38M |
| Return on Equity | -0.04 | -0.03 | 0.20 | -0.07 | -0.10 | -0.09 | -0.08 | -0.07 | -0.05 | -0.04 | -0.06 | -0.08 |
DNTH News
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Alyeska Investment Group L.P. Has $14.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases